NordestgaardBG.Triglyceride‐rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res2016;
118: 547–563.
2.
Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111–188.
3.
MahleyRWHuangY.Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.J Clin Invest2007;
117: 94–98.
4.
BorenJChapmanJMKraussRM, et al.
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J2020;
0: 1–28.
5.
ReinerZ.Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis2013;
23: 799807.
6.
PandorAAraRMTumurI, et al.
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med2009;
265: 568–580.
7.
ChapmanMJRedfernJSMcGovernME, et al.
Niacin and fibrates in athero-genic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther2010;
126: 314–345.
8.
BhattDLStegPGMillerM, et al.
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med2019;
380: 11–22.
9.
Vallejo-VazAJLeiterLADel PratoS, et al. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY Phase 3 trials with alirocumab. Eur J Prev Cardiol. 2020; 27: 1663–1674.
10.
LainaAGatsiouAGeorgiopoulosG, et al.
RNA therapeutics in cardiovascular precision medicine. Front Physiol2018;
9: 953.
